Galcanezumab for preventing migraine – guidance (TA659)

Galcanezumab is recommended for prophylaxis of episodic and chronic migraine, only if at least 3 preventive drug treatments have failed. Treatment should be stopped after 12 weeks if the headache frequency does not reduce by 50% with episodic, and 30% with chronic migraine.

National Institute for Health and Care Excellence